The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome
The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL...
Gespeichert in:
| Veröffentlicht in: | Current rheumatology reports 2015-03, Vol.17 (3), p.14-14, Article 14 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 3 |
| container_start_page | 14 |
| container_title | Current rheumatology reports |
| container_volume | 17 |
| creator | Artim-Esen, Bahar Diz-Küçükkaya, Reyhan İnanç, Murat |
| description | The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy. |
| doi_str_mv | 10.1007/s11926-014-0494-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1661328037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1661328037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-81b8842751534c7de8d1a757dd6a00f35b421cbed10c1bc2fc94b6e0bc9ba2393</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EoqXwACwoI0vg-JI4GauKm1QEUsts-ZbWVWKHOBn69qRqYWSwbMnf_-ucD6FbDA8YgD9GjEuSp4BZCqxkaXGGpjijLM0p8PPDm9CUcs4m6CrGHQABKOglmpCMM-BAp-hzvbXJym28q5yWXttEepO8Sy83trG-T0KVrLddaFTQ-z601juZOJ_Mfe_abYjjqV3rTLLaezNi9hpdVLKO9uZ0z9DX89N68ZouP17eFvNlqhmGPi2wKgpGeHaYV3NjC4Mlz7gxuQSoaKYYwVpZg0FjpUmlS6ZyC0qXShJa0hm6P_a2XfgebOxF46K2dS29DUMUOM8xJQVQPqL4iOouxNjZSrSda2S3FxjEQaQ4ihSjSHEQKYoxc3eqH1RjzV_i19wIkCMQxy-_sZ3YhaHz48r_tP4ALwZ-eQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1661328037</pqid></control><display><type>article</type><title>The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Artim-Esen, Bahar ; Diz-Küçükkaya, Reyhan ; İnanç, Murat</creator><creatorcontrib>Artim-Esen, Bahar ; Diz-Küçükkaya, Reyhan ; İnanç, Murat</creatorcontrib><description>The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.</description><identifier>ISSN: 1523-3774</identifier><identifier>EISSN: 1534-6307</identifier><identifier>DOI: 10.1007/s11926-014-0494-8</identifier><identifier>PMID: 25740703</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Antiphospholipid Syndrome (D Erkan ; Antiphospholipid Syndrome - complications ; Glucocorticoids - therapeutic use ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Medicine ; Medicine & Public Health ; Prednisone - therapeutic use ; Rheumatology ; Section Editor ; Thrombocytopenia - drug therapy ; Thrombocytopenia - etiology ; Topical Collection on Antiphospholipid Syndrome ; Treatment Outcome</subject><ispartof>Current rheumatology reports, 2015-03, Vol.17 (3), p.14-14, Article 14</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-81b8842751534c7de8d1a757dd6a00f35b421cbed10c1bc2fc94b6e0bc9ba2393</citedby><cites>FETCH-LOGICAL-c410t-81b8842751534c7de8d1a757dd6a00f35b421cbed10c1bc2fc94b6e0bc9ba2393</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11926-014-0494-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11926-014-0494-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25740703$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Artim-Esen, Bahar</creatorcontrib><creatorcontrib>Diz-Küçükkaya, Reyhan</creatorcontrib><creatorcontrib>İnanç, Murat</creatorcontrib><title>The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome</title><title>Current rheumatology reports</title><addtitle>Curr Rheumatol Rep</addtitle><addtitle>Curr Rheumatol Rep</addtitle><description>The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.</description><subject>Antiphospholipid Syndrome (D Erkan</subject><subject>Antiphospholipid Syndrome - complications</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Prednisone - therapeutic use</subject><subject>Rheumatology</subject><subject>Section Editor</subject><subject>Thrombocytopenia - drug therapy</subject><subject>Thrombocytopenia - etiology</subject><subject>Topical Collection on Antiphospholipid Syndrome</subject><subject>Treatment Outcome</subject><issn>1523-3774</issn><issn>1534-6307</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOwzAUhi0EoqXwACwoI0vg-JI4GauKm1QEUsts-ZbWVWKHOBn69qRqYWSwbMnf_-ucD6FbDA8YgD9GjEuSp4BZCqxkaXGGpjijLM0p8PPDm9CUcs4m6CrGHQABKOglmpCMM-BAp-hzvbXJym28q5yWXttEepO8Sy83trG-T0KVrLddaFTQ-z601juZOJ_Mfe_abYjjqV3rTLLaezNi9hpdVLKO9uZ0z9DX89N68ZouP17eFvNlqhmGPi2wKgpGeHaYV3NjC4Mlz7gxuQSoaKYYwVpZg0FjpUmlS6ZyC0qXShJa0hm6P_a2XfgebOxF46K2dS29DUMUOM8xJQVQPqL4iOouxNjZSrSda2S3FxjEQaQ4ihSjSHEQKYoxc3eqH1RjzV_i19wIkCMQxy-_sZ3YhaHz48r_tP4ALwZ-eQ</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Artim-Esen, Bahar</creator><creator>Diz-Küçükkaya, Reyhan</creator><creator>İnanç, Murat</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome</title><author>Artim-Esen, Bahar ; Diz-Küçükkaya, Reyhan ; İnanç, Murat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-81b8842751534c7de8d1a757dd6a00f35b421cbed10c1bc2fc94b6e0bc9ba2393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiphospholipid Syndrome (D Erkan</topic><topic>Antiphospholipid Syndrome - complications</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Prednisone - therapeutic use</topic><topic>Rheumatology</topic><topic>Section Editor</topic><topic>Thrombocytopenia - drug therapy</topic><topic>Thrombocytopenia - etiology</topic><topic>Topical Collection on Antiphospholipid Syndrome</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Artim-Esen, Bahar</creatorcontrib><creatorcontrib>Diz-Küçükkaya, Reyhan</creatorcontrib><creatorcontrib>İnanç, Murat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current rheumatology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Artim-Esen, Bahar</au><au>Diz-Küçükkaya, Reyhan</au><au>İnanç, Murat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome</atitle><jtitle>Current rheumatology reports</jtitle><stitle>Curr Rheumatol Rep</stitle><addtitle>Curr Rheumatol Rep</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>17</volume><issue>3</issue><spage>14</spage><epage>14</epage><pages>14-14</pages><artnum>14</artnum><issn>1523-3774</issn><eissn>1534-6307</eissn><abstract>The association between antiphospholipid antibodies (aPL) and clinical problems goes beyond what is stated in the antiphospholipid syndrome (APS) classification criteria, namely thrombosis and pregnancy morbidity, and thrombocytopenia is the most common non-criteria hematologic manifestation of aPL with a frequency ranging from 20 to 50 %. Thrombocytopenia is rarely severe, and hemorrhage is far less common than thrombosis. However, when anticoagulation is considered, it may constitute a clinical problem with increased bleeding risk. Furthermore, thrombocytopenia represents a risk factor for thrombosis in aPL-positive patients. Therefore, it is important to understand the pathogenesis and the clinical associations of thrombocytopenia to build the right medical approach in aPL-positive patients. In this paper, we review the literature on aPL/APS-associated thrombocytopenia and briefly discuss the other conditions that can result in thrombocytopenia as they have commonalities with APS and their recognition is important to establish the most appropriate treatment strategy.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>25740703</pmid><doi>10.1007/s11926-014-0494-8</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3774 |
| ispartof | Current rheumatology reports, 2015-03, Vol.17 (3), p.14-14, Article 14 |
| issn | 1523-3774 1534-6307 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1661328037 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antiphospholipid Syndrome (D Erkan Antiphospholipid Syndrome - complications Glucocorticoids - therapeutic use Humans Immunoglobulins, Intravenous - therapeutic use Medicine Medicine & Public Health Prednisone - therapeutic use Rheumatology Section Editor Thrombocytopenia - drug therapy Thrombocytopenia - etiology Topical Collection on Antiphospholipid Syndrome Treatment Outcome |
| title | The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T17%3A52%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Significance%20and%20Management%20of%20Thrombocytopenia%20in%20Antiphospholipid%20Syndrome&rft.jtitle=Current%20rheumatology%20reports&rft.au=Artim-Esen,%20Bahar&rft.date=2015-03-01&rft.volume=17&rft.issue=3&rft.spage=14&rft.epage=14&rft.pages=14-14&rft.artnum=14&rft.issn=1523-3774&rft.eissn=1534-6307&rft_id=info:doi/10.1007/s11926-014-0494-8&rft_dat=%3Cproquest_cross%3E1661328037%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1661328037&rft_id=info:pmid/25740703&rfr_iscdi=true |